



30 March 2021

## **dorsaVi advances Medtronic relationship with Master Services Agreement**

### **Key highlights**

- **dorsaVi has entered into a master services agreement (MSA) with Medtronic which progresses the commercial relationship between the two companies**
- **The initial statement of work (SOW) under the agreement is worth approximately US\$330k to dorsaVi and is expected to run for approximately 12 months, involving the collaborative data analysis, tailoring and application of dorsaVi's technology**
- **The deal follows the initial evaluation agreement announced in December 2020**

**Melbourne, Australia, 30 March 2021:** dorsaVi (ASX: DVL) (**dorsaVi** or the **Company**) is pleased to announce it has entered into a MSA with Medtronic to progress to the second stage of the Company's relationship with Medtronic, following the initial evaluation agreement in December 2020.

The second stage agreement is worth approximately US\$330k, whereby dorsaVi will work with Medtronic to perform further data capture and data analysis and look to optimise the technology. The project will be conducted over approximately 12 months and will involve analysis of data on patients wearing dorsaVi medical grade wearable sensors. The agreement follows the evaluation agreement entered in December 2020, where Medtronic staff would work alongside leading clinicians to evaluate the effectiveness of dorsaVi's technology in assessing patients undergoing surgical evaluation.

### **Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, said:**

*"We are delighted to advance our relationship with Medtronic and continue to help them achieve better clinical evaluations for patients. This second stage agreement is the continued evaluation of our technology, as it follows on from our work as part of the initial evaluation agreement signed in December 2020. Aligned with our channel partnership strategy, we are excited by the opportunities with Medtronic, a world-leading medical technology, services and solutions company."*

Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies – alleviating pain, restoring health and extending life for millions of people around the world.

– ENDS –

**For further information about dorsaVi, please contact:**

**dorsaVi**

Andrew Ronchi  
Chief Executive Officer  
+61 417 882 267  
[ar@dorsavi.com](mailto:ar@dorsavi.com)

**dorsaVi**

Matt May  
General Manager  
+61 409 324 949  
[mmay@dorsavi.com](mailto:mmay@dorsavi.com)

**Investor Enquiries**

Ivan Lee  
Vesparum Capital  
+61 3 8582 4800  
[dorsavi@vesparum.com](mailto:dorsavi@vesparum.com)

The release of this announcement was authorised by the Disclosure Committee of the dorsaVi Board.

***About dorsaVi***

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into the physical therapy (physiotherapists) market, hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance. dorsaVi's ViPerform is being used in the U.S. by the National Basketball Association (NBA), the Major League Soccer (MLS) and the National Football League (NFL). It is also used by the AFL and NRL clubs in Australia, by the English Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally. dorsaVi's Telehealth provides a virtual clinic, enabling clinicians to do business differently and take their patient consultations online.

Further information is available at [www.dorsavi.com](http://www.dorsavi.com)